BioNTech and Fosun Pharma Jointly Announce the Arrival of the First Batch of COVID-19 mRNA Vaccine in Hong Kong and Macau
Release time:2021-02-27
Content sourced from：Fosun Pharma
Page View：
MAINZ, GERMANY, and SHANGHAI, CHINA, 27 February 2021 — BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma” or “Group”; Stock Code: 600196.SH, 02196.HK) jointly announced that the first batch of COVID-19 mRNA vaccine COMIRNATY® (also known as BNT162b2, Chinese product name: 復必泰TM) has arrived in Hong Kong International Airport from Frankfurt Airport in Germany on the morning of 27 February 2021. The first batch of COVID-19 mRNA vaccine will be supplied to Hong Kong and Macau respectively. Those to Macau will be delivered through Hong Kong-Zhuhai-Macau Bridge.
Wu Yifang, Chairman and CEO of Fosun Pharma said, “We sincerely appreciate about the support from Hong Kong and Macau Government and efforts from all our partners. The past year was marked by the onslaught of the COVID-19 pandemic. Vaccine has become the important way of containing the pandemic. We are confident to victory over the pandemic and we will also cooperate closely with Hong Kong and Macau Government regarding vaccination program to provide strong protection for every family in Hong Kong and Macau.”
Ugur Sahin, M.D., CEO and Co-founder of BioNTech added, “Together with our partner Fosun Pharma, we are working relentlessly to support the roll-out of COMIRNATY® in Hong Kong. This forms part of our global effort in ensuring worldwide access to our well-tolerated and highly efficacious vaccines.”
On 16 March 2020, BioNTech and Fosun Pharma announced a strategic collaboration to work jointly on the development and commercialization of COVID-19 vaccine products in Greater China based on BioNTech’s proprietary mRNA technology platform.
COMIRNATY® (Chinese product name: 復必泰TM) is a mRNA COVID-19 vaccine for prevention of COVID-19 caused by SARS-CoV-2 virus, which is effective for adults and teenagers over 16 years old. The vaccine protects against COVID-19 by causing the immune system (the body's natural defense system) to generate antibodies and blood cells that against the virus.
According to the data from the global Phase 3 Clinical trial, BioNTech’s mRNA-based COVID-19 vaccine met all primary efficacy endpoints, demonstrating effectiveness of 95% in preventing COVID-19 in adults and 94% in adults over 65 years of age. Efficacy in the trial was consistent across age, gender, race and ethnicity. This COVID-19 mRNA vaccine has been granted Authorization for Emergency Use in Hong Kong on 25 January 2021 and Special Import Authorization in Macau on 23 February 2021. It has also been authorized for use by the health regulatory authorities of over 60 countries and regions, including the United Kingdom, the United States, Canada, and the European Union.
mRNA is a natural molecule that acts like a blueprint providing instructions for human cells to make a target protein, or antigen, which activates the body’s immune response against the respective virus. mRNA vaccines utilize the genetic sequencing of the virus but not the virus itself. Therefore, mRNA vaccine has no viral component and no risk of infection. Also, mRNA vaccine has advantages such as short development cycle, enabling rapid development of novel vaccine candidates to meet viral mutations; the dual mechanism of humoral and T-cell immunity is immunogenic and does not require adjuvants; it is easy to mass-produce and supports the goal of global supply.
Wu Yifang, Chairman and CEO of Fosun Pharma said, “We sincerely appreciate about the support from Hong Kong and Macau Government and efforts from all our partners. The past year was marked by the onslaught of the COVID-19 pandemic. Vaccine has become the important way of containing the pandemic. We are confident to victory over the pandemic and we will also cooperate closely with Hong Kong and Macau Government regarding vaccination program to provide strong protection for every family in Hong Kong and Macau.”
Ugur Sahin, M.D., CEO and Co-founder of BioNTech added, “Together with our partner Fosun Pharma, we are working relentlessly to support the roll-out of COMIRNATY® in Hong Kong. This forms part of our global effort in ensuring worldwide access to our well-tolerated and highly efficacious vaccines.”
On 16 March 2020, BioNTech and Fosun Pharma announced a strategic collaboration to work jointly on the development and commercialization of COVID-19 vaccine products in Greater China based on BioNTech’s proprietary mRNA technology platform.
COMIRNATY® (Chinese product name: 復必泰TM) is a mRNA COVID-19 vaccine for prevention of COVID-19 caused by SARS-CoV-2 virus, which is effective for adults and teenagers over 16 years old. The vaccine protects against COVID-19 by causing the immune system (the body's natural defense system) to generate antibodies and blood cells that against the virus.
According to the data from the global Phase 3 Clinical trial, BioNTech’s mRNA-based COVID-19 vaccine met all primary efficacy endpoints, demonstrating effectiveness of 95% in preventing COVID-19 in adults and 94% in adults over 65 years of age. Efficacy in the trial was consistent across age, gender, race and ethnicity. This COVID-19 mRNA vaccine has been granted Authorization for Emergency Use in Hong Kong on 25 January 2021 and Special Import Authorization in Macau on 23 February 2021. It has also been authorized for use by the health regulatory authorities of over 60 countries and regions, including the United Kingdom, the United States, Canada, and the European Union.
mRNA is a natural molecule that acts like a blueprint providing instructions for human cells to make a target protein, or antigen, which activates the body’s immune response against the respective virus. mRNA vaccines utilize the genetic sequencing of the virus but not the virus itself. Therefore, mRNA vaccine has no viral component and no risk of infection. Also, mRNA vaccine has advantages such as short development cycle, enabling rapid development of novel vaccine candidates to meet viral mutations; the dual mechanism of humoral and T-cell immunity is immunogenic and does not require adjuvants; it is easy to mass-produce and supports the goal of global supply.
share
